1. "Leukemia and Lymphoma"
Formats
  1. Journal Article (226)
  2. Meeting Abstract (13)
  3. Research Letter (13)
  4. Review (11)
  5. Correspondence (8)
  6. Editorial (8)
  7. Conference Paper (6)
Groups
  1. Department of Medicine (209)
  2. Hematologic Malignancies, Division of (204)
  3. Center for Hematologic Malignancies (197)
  4. Lymphoma (78)
  5. Adult Leukemia (68)
  6. Survivorship Research (61)

More Groups

People
  1. Sergio Giralt (29)
  2. Andrew Zelenetz (28)
  3. Martin Tallman (25)
  4. Steven Horwitz (17)
  5. Anthony Mato (16)
  6. Carl Landgren (16)

More People

Years
  1. 2024 (4)
  2. 2023 (22)
  3. 2022 (25)
  4. 2021 (17)
  5. 2020 (32)
  6. 2019 (18)

More Years

Publications
  1. Leukemia and Lymphoma (285)
Publishers
  1. Taylor & Francis Group (285)

Results (285)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies
    Journal Article

    Stein, E. M.; Fathi, A. T.; Harb, W. A.; Colak, G.; Fusco, A.; Mangan, J. K.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • The 5th edition of the World Health Organization classification of mature lymphoid and stromal tumors–An overview and update
    Review

    Attygalle, A. D.; Chan, J. K. C.; Coupland, S. E.; Du, M. Q.; Ferry, J. A.; de Jong, D.; Gratzinger, D.; Lim, M. S.; Naresh, K. N.; Nicolae, A.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Journal Article

    Grieve, C.; Joseph, A.; Drullinsky, P.; Zelenetz, A. D.; Hamlin, P.; Kumar, A.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
    Journal Article

    Hess, G.; Dreyling, M.; Oberic, L.; Gine, E.; Zinzani, P. L.; Linton, K.; Vilmar, A.; Jerkeman, M.; Chen, J. M. H.; Ohler, A.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab
    Research Letter

    Stuver, R.; Vardhana, S. A.; Bedmutha, A.; Chan, K. K.; Mirtcheva-Trocheva, R.; Nosov, A.; Schöder, H.; Moskowitz, A.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma
    Journal Article

    Dahi, P. B.; Kenny, S.; Flynn, J.; Devlin, S. M.; Ruiz, J. D.; Chinapen, S. A.; Lahoud, O. B.; Matasar, M. J.; Moskowitz, C. H.; Perales, M. A.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
    Journal Article

    Freret, M. E.; Tringale, K. R.; Boe, L.; Imber, B. S.; Joffe, E.; Yahalom, J.; Hajj, C.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression
    Journal Article

    Stein, E. M.; de Botton, S.; Cluzeau, T.; Pigneux, A.; Liesveld, J. L.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Braun, T.; Roboz, G. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma
    Journal Article

    Fried, S.; Shkury, E.; Itzhaki, O.; Sdayoor, I.; Yerushalmi, R.; Shem-Tov, N.; Danylesko, I.; Jacoby, E.; Shouval, R.; Kedmi, M.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Mature T-cell and NK-cell lymphoma involvement of the central nervous system: A single center experience
    Journal Article

    Ma, H.; Marchi, E.; O’Connor, O. A.; Lue, J. K.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save